Association between acetylsalicylic acid and the risk of dialysis-related infections or septicemia among incident hemodialysis patients: a nested case–control study

Table 3 Adjusted odds ratios for dialysis-related infection or septicemia

Variable	Crude OR				Adjusted OR^a
Variable	OR	95 % CI			OR	95 % CI
Age (by 1 year)	0.87	0.62	,	1.23	0.86	0.71	,	1.04
Race
Black	1.35	0.88	,	2.08	1.37	0.9	,	2.08
Caucasian	1.00	Reference			1.00	Reference
Other	0.94	0.67	,	1.32	0.95	0.7	,	1.3
BMI (by 5 kg/m²)	1.05	0.97	,	1.14	1.01	0.93	,	1.11
Smoking	1.12	0.85	,	1.47	1.1	0.84	,	1.44
Co-morbidities
Cardiovascular disease	1.11	0.90	,	1.36	1.01	0.79	,	1.28
Cerebrovascular disease	1.16	0.89	,	1.50	1.1	0.84	,	1.43
Chronic pulmonary disease	1.18	0.96	,	1.46	1.15	0.92	,	1.43
Chronic liver disease	0.77	0.40	,	1.47	0.71	0.38	,	1.32
Congestive heart failure	1.05	0.86	,	1.29	0.91	0.73	,	1.14
Diabetes	1.31	1.07	,	1.61	1.3	1.05	,	1.62
Hyperlipidemia	1.07	0.87	,	1.31	0.98	0.78	,	1.22
Hypertension	1.22	0.78	,	1.90	1.17	0.77	,	1.77
Malignancy	1.13	0.87	,	1.46	1.17	0.91	,	1.51
Peripheral vascular disease	1.09	0.88	,	1.34	1.01	0.81	,	1.24
ASA daily dose
Unexposed	1.00	Reference			1.00	Reference
80-324 mg	0.99	0.80	,	1.24	1.02	0.82	,	1.26
≥ 325 mg	1.06	0.78	,	1.44	1.17	0.87	,	1.58
Other medication use
Anticoagulant	1.57	1.26	,	1.96	1.61	1.29	,	2.01
Antiplatelet	0.96	0.70	,	1.32	0.97	0.7	,	1.33
Laboratory data
Albumin (by 10 g/L)	0.85	0.71	,	1.02	0.93	0.79	,	1.10
eGFR (ml/min•1.73 m²)	1.00	0.97	,	1.03	1.00	0.97	,	1.03
Hemoglobin (by 10 g/L)	0.93	0.88	,	0.99	0.94	0.89	,	1.00

Unit conversion: Albumin, multiply by 10 to convert g/dL to g/L; Hemoglobin, multiply by 10 to convert g/dL to g/L
BMI body mass index; eGFR estimated glomerular filtration rate
^aAdjusted for demographics, body mass index, smoking, comorbidities, anticoagulant use, antiplatelet use, and laboratory values

ISSN: 1471-2369